Glaucoma, Glaucoma, Open-Angle
Conditions
Brief summary
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Interventions
Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina
DEVICESham Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Patients receive sham treatment (no active stimulation) every other day via a headband.
Sponsors
Stanford University
NYU Langone Health
Otto-von-Guericke University Magdeburg
Wills Eye
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participant must be at least 18. 2. Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE). 3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false positives do not exceed 20%. 4. Visual Field Index between 10 and 90% 5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal) 6. In the opinion of the investigator the participant's eye pressure must be clinically stable. 7. If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study. 8. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.
Exclusion criteria
1. Participant is unable to comply with study procedures or follow-up visits. 2. Participant has a history of ocular herpes zoster. 3. Participant has pathological nystagmus 4. Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa. 5. Participant has evidence of corneal opacification or lack of optical clarity. 6. Participant has uveitis or other ocular inflammatory disease. 7. Participant has any electric or electronic implants such as a pacemaker. 8. Participant has acute conjunctivitis. 9. Participant has acute autoimmune disease. 10. Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration. 11. Participant is pregnant or lactating. 12. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia. 13. Unresected brain tumors 14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable 15. Patients with any skin damage. 16. Children and comatose patients. 17. Patients with history of epileptic seizure within the last 10 years. 18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes. 19. Self-reported alcohol or illicit drug addictions within the last 12 months. 20. Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and/or unable to confirm follow-up participation 21. Prior participation in a vision training/stimulation study in the last 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in visual field assessed by Humphrey Visual Field Index (VFI). | Baseline through 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in visual field assessed by Humphrey Mean Deviation (MD). | Baseline through 6 months | — |
| Change from baseline in visual field assessed by Pelli-Robson Contrast Sensitivity. | Baseline through 6 months | Pelli-Robson is a standard for measuring contrast sensitivity. It is measured on a 0-16 scale. Normal contrast sensitivity is between 12 and 14 with 0 being worst and 16 being best. |
| Change from baseline in visual acuity as assessed by the Snellen visual acuity test. | Baseline through Month 6 | The Snellen test is a standard eye chart test used to test eyesight. |
Countries
Germany, United States
Contacts
PRINCIPAL_INVESTIGATORJeffrey L Goldberg, MD PhD
Stanford University
PRINCIPAL_INVESTIGATORBernhard Sable, PhD
Otto-von-Guericke University Magdeburg
PRINCIPAL_INVESTIGATORJoeseph F Panarelli, MD
NYU- Langone
PRINCIPAL_INVESTIGATORJoel Schuman, MD,FACS
Wills Eye
Outcome results
None listed